Edition:
United Kingdom

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

22.85USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$22.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
75,711
52-wk High
$43.30
52-wk Low
$22.09

Select another date:

Tue, Feb 27 2018

BRIEF-Theravance Biopharma Q4 Revenue $4.5 Million

* THERAVANCE BIOPHARMA, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

BRIEF-Theravance, Mylan Announce FDA Acceptance Of Marketing Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Source text for Eikon: Further company coverage:

BRIEF-Theravance Biopharma ‍Files Supplemental NDA With U.S. FDA For Use Of Trelegy Ellipta​

* THERAVANCE BIOPHARMA HIGHLIGHTS SUBMISSION OF LANDMARK IMPACT DATA TO FDA TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA

BRIEF-Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD

* Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD Source text for Eikon: Further company coverage:

BRIEF-Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin

* Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease

BRIEF-Theravance Biopharma posts Q3 loss of $1.27 per share

* Theravance biopharma, inc. Reports third quarter 2017 financial results and provides business update

BRIEF-Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin

* Theravance Biopharma and mylan report additional positive phase 3 data for Revefenacin (TD-4208) in multiple presentations at 2017 Chest Annual Meeting

Select another date: